c/s-Diammine-1,1-cyclobutane dicarboxylate platinum(ll) (CBDCA, JM8) is a nonnephrotoxic analogue of cisplatin cur rently undergoing clinical evaluation. Pharmacokinetic studies have been performed in patients receiving CBDCA (20 to 520 mg/sq m) as a 1-hr infusion without hydration or diuresis. Follow ing the end of the infusion, plasma levels of total platinum and ultrafilterable (M, < 50,000)...

Platinum bis-amidine complexes (both the cis and trans isomers) are stable in acetone and chlorinated solvents but are unstable in protic solvents such as methanol or water. In the latter solvents an initial cis/trans isomerization leads to formation of an equilibrium mixture with a cis/trans ratio of about 1:4; subsequently a dinuclear platinum(III) complex (1) is formed under aerobic conditio...

This study investigated the oxidation of ascorbic acid (Vitamin C) using a platinum nanoparticle electrode coated with an iodine monolayer, called a modified electrode. The electrode were grown using the cyclic voltammetry technique and the electrochemical measurements were taken using the cyclic voltammetry and chronoamperometric technique. In the case of platinum nanoparticle electrode modifi...

a chelating resin is prepared by condensation polymerization of aniline with formaldehyde andcharacterized by ft-ir, elemental analysis and studied for the preconcentration and determination of traceplatinum ion from environmental water sample using inductively coupled plasma-atomic emission spectroscopy(icp-aes). the optimum ph value for sorption of the metal ions was 5. the maximum adsorption...

Treatment of [{Ti(η5-C5Me5)(μ-NH)}3(μ3-N)] (1) with one equivalent of [Ni(cod)2] (cod = 1,5-cyclooctadiene) in toluene at 60–80 °C and subsequent addition of diphenylacetylene, trans-stilbene or triphenylphosphane afforded the nickel(0) complexes [LNi{(μ3-NH)3Ti3(η5-C5Me5)3(μ3-N)}] (L = PhCCPh (2), PhCH≡CHPh (3), PPh3 (4)). The nickel(II) complex [I2Ni{(μ3-NH)3Ti3(η5-C5Me5)3(μ3-N)}] (5) was pre...

Platinum(IV)-based anticancer prodrugs have attracted much attention due to their relative inertness under physiological conditions, being activated inside cells, and their capacity for functionalization with a variety of small-molecule or macromolecule moieties. Novel asymmetric platinum(IV) compounds synthesized through expedient and unique methods are desired. Here we utilize N-bromosuccinim...

The majority of epithelial ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma (PPA) patients experience disease recurrence even though they receive standard treatment. The treatment outcome after recurrence depended on the interval time between the time to complete platinum-based chemotherapy until the time to replapse that we called a platinum-free interval. In patient...

Platinum nanoparticles, which are used as catalysts in Proton Exchange Membrane Fuel Cells (PEMFC), tend to degrade after long-term operation. We discriminate the following mechanisms of the degradation: poisoning, migration and coalescence, dissolution, and electrochemical Ostwald ripening. There are two ways to tackle this problem. The first option involves formulation of durable catalyst, wh...

Platinum-based chemotherapy regimens are frequently used in patients with triple-negative breast cancer (TNBC). The aim of the current study was to assess whether or not platinum-based chemotherapy is associated with an increased time to progression when compared with non-platinum-based regimens in TNBC and non-TNBC. A retrospective analysis was conducted within a cohort of patients with metast...

Hitherto, platinum-based combinations are world-wide accepted regimens in the treatment of advanced non-small cell lung cancer (NSCLC) due to a clear survival improvement using various platinum-based doublets in comparison with best supportive care only. However, treatment-allocated time and period with high grade toxicity could be considered as wasted from the patient point of view and the hig...